trending Market Intelligence /marketintelligence/en/news-insights/trending/cgtxbwcvc8l_rydwspttdq2 content esgSubNav
In This List

Acasti Pharma gets Nasdaq noncompliance notice

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Acasti Pharma gets Nasdaq noncompliance notice

Acasti Pharma Inc. said it fell out of Nasdaq's bid price listing requirement.

The Canadian biopharmaceutical company, the bid price of which was below the exchange's $1 minimum requirement, has 180 calendar days, or until Dec. 3, to regain compliance.

The notice has no immediate effect on Acasti Pharma's listing.